Combination Therapies for Advanced Melanoma

This information was originally presented at the NCCN 2017 Oncology Fellows Program: New Horizons in Quality Cancer Care™ held on March 26, 2017.

The purpose of this program is to educate future oncology practitioners about the application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and other evidence-based treatment principles in the management of significant cancer types and supportive care issues.

Target Audience

These educational programs are designed to meet the educational needs of medical, surgical, and radiation oncology fellows.

Learning Objectives

Following this program, participants should be able to:

  • For first-line treatment of advanced melanoma, list factors to consider when determining whether a patient should receive (1) a checkpoint immunotherapy versus a BRAF-targeted therapy and (2) a monotherapy versus a combination therapy.
  • For second-line or subsequent therapy in patients with advanced melanoma, list appropriate treatment options based on a patient’s response to prior therapy.
Additional information
Supporters: 

This activity is supported by educational grants from: AstraZeneca; Pfizer; Prometheus Laboratories Inc.; supported by educational funding provided by Amgen; supported by an independent medical education grant from Bristol-Myers Squibb; and supported by an independent educational grant from TESARO. 

Course summary
Course opens: 
05/15/2017
Course expires: 
03/01/2018
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2017 Oncology Fellows Program: New Horizons in Quality Cancer Care™

April Salama, MD
Duke Cancer Institute

 

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support.

The faculty listed below discloses the following relevant financial relationships:
April Salama, MD
Bristol-Myers Squibb Company: Scientific Advisor

The activity planning staff listed below has no relevant financial interests to disclose:
Kimberly Bayer; Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until February 7, 2017); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until February 3, 2017)

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Anita Engh, PhD

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Continuing education credit and contact hours are not available for this learning activity.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need: